183 related articles for article (PubMed ID: 15731202)
1. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
Pineda JA; Macías J
J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
3. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
[TBL] [Abstract][Full Text] [Related]
4. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
[TBL] [Abstract][Full Text] [Related]
5. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients.
Vergara S; Macías J; Mira JA; García-García JA; Merchante N; del Valle J; Abdel-Kader L; Lozano F; Gómez-Mateos JM; Pineda JA
J Antimicrob Chemother; 2007 Jan; 59(1):87-91. PubMed ID: 17095528
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.
Schiavini M; Angeli E; Mainini A; Zerbi P; Duca PG; Gubertini G; Vago L; Fociani P; Giorgi R; Cargnel A
HIV Med; 2006 Jul; 7(5):331-7. PubMed ID: 16945079
[TBL] [Abstract][Full Text] [Related]
7. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
Connoy A; Turner J; Núñez M
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
[TBL] [Abstract][Full Text] [Related]
8. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus.
Neff GW; Shire NJ; Rudich SM
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S50-5. PubMed ID: 16265614
[TBL] [Abstract][Full Text] [Related]
9. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
[TBL] [Abstract][Full Text] [Related]
10. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Stone SF; Lee S; Keane NM; Price P; French MA
J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
[TBL] [Abstract][Full Text] [Related]
11. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
Kumar R; Singla V; Kacharya Sk
Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
[TBL] [Abstract][Full Text] [Related]
12. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
Vogel M; Rockstroh JK
Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
[TBL] [Abstract][Full Text] [Related]
13. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Halota W; Pawłowska M
Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
[TBL] [Abstract][Full Text] [Related]
14. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
[TBL] [Abstract][Full Text] [Related]
15. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
Verma S
J Antimicrob Chemother; 2006 Sep; 58(3):496-501. PubMed ID: 16854955
[TBL] [Abstract][Full Text] [Related]
16. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
Neuman MG; Monteiro M; Rehm J
Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
[TBL] [Abstract][Full Text] [Related]
17. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
18. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.
Petrovic LM
Liver Int; 2007 Jun; 27(5):598-606. PubMed ID: 17498243
[TBL] [Abstract][Full Text] [Related]
19. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
[TBL] [Abstract][Full Text] [Related]
20. Impact of HAART on liver histology of HIV/HCV coinfected patients.
De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
